Belvedere Trading’s PharmaCyte Biotech PMCB Stock Holding History

Belvedere Trading’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,600	Closed	-$54.5K	–	1327
2022 Q4	$54.5K	Buy	+18,600	New	+$53.3K	﹤0.01%	622

Other funds holding PMCB

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Belvedere Trading's PMCB Position: Q2 2023 in Review

Belvedere Trading sold out of PharmaCyte Biotech (PMCB) in Q2 2023, closing a stake of 7,135 shares — an estimated $20.8K sold.

Belvedere Trading first reported a position in PMCB in Q1 2023 and held it in 1 quarter. The position peaked at $20.8K in Q1 2023. 29 funds tracked by Wall St. Rank hold PMCB as of Q2 2023.

Belvedere Trading reported no remaining PharmaCyte Biotech position as of Q2 2023 after selling out during the quarter.
Belvedere Trading sold 7,135 PharmaCyte Biotech shares in Q2 2023, an estimated $20.8K.
Belvedere Trading first reported a position in PharmaCyte Biotech in Q1 2023 and held it in 1 quarter.
Belvedere Trading's PharmaCyte Biotech position peaked at $20.8K in Q1 2023.
29 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.